Corcept Therapeutics recently announced successful results from its ROSELLA trial for relacorilant plus nab-paclitaxel, indicating a notable positive stride in treatment for platinum-resistant ovarian cancer. This announcement, emphasizing a significant improvement in progression-free and overall survival, aligns with the company’s 8% share price uptick over the last quarter. Despite broader market challenges and a slide in major indices like the S&P 500 and Nasdaq, Corcept’s pharmaceutical advancements stood out, boosting investor sentiment amid a backdrop of tariff concerns and economic unease.

Buy, Hold or Sell Corcept Therapeutics? View our complete analysis and fair value estimate and you decide.

Uncover 12 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

Over the past five years, Corcept Therapeutics has achieved a significant total return of 373.40%. This impressive performance has been underpinned by several key developments. A major driver was the successful results from pivotal trials such as ROSELLA, which improved progression-free survival in ovarian cancer patients. The acceptance of a New Drug Application (NDA) for relacorilant treatment of hypercortisolism further bolstered market confidence, supported by positive outcomes from the GRACE and GRADIENT studies.

In addition to promising clinical advancements, Corcept has delivered strong financial results, with full-year 2024 net income rising to US$141.21 million, up from US$106.14 million the previous year. Despite some operational challenges, such as those faced with a pharmacy partner, annual guidance revisions and an expanding oncology division contributed positively. Over the past year, Corcept outperformed the US Pharmaceuticals industry, which returned just 2% during the same timeframe, highlighting its growth trajectory and market differentiation.

Understand Corcept Therapeutics' track record by examining our performance history report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:CORT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com